Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.

European journal of cancer (Oxford, England : 1990) - 3 Jun 2026

Sikkema Barend J, Veerman Marijn, Hoop Esther Oomen-de, Paats Marthe S, Mathijssen Ron H J, Dingemans Anne-Marie C

Abstract excerpt

INTRODUCTION: This study explores the associations between computed tomography (CT)-derived changes in body composition during the first three months of osimertinib monotherapy, systemic osimertinib exposure, and treatment outcomes in patients with advanced EGFR+ NSCLC. MATERIALS AND METHODS: Patients initiating osimertinib between January 2016 and January 2022 were selected from the START-TKI biomarker study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Composition

Share to Indoles

Share to Muscle, Skeletal

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 41997038
DOI: 10.1016/j.ejca.2026.116742

Genes

EGFR
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.PMID 41997038Read ↗

The Relationship Between Efficacy and Safety of Osimertinib Blood Concentration in Patients With EGFR Mutation-positive Lung Cancer: A Prospective Observational Study.Semantic proximity Read ↗

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Body composition measures as a determinant of Alpelisib related toxicitySemantic proximity Read ↗

Body composition measures as a determinant of Alpelisib related toxicity.Semantic proximity Read ↗

Low skeletal muscle radiodensity predicts response to avelumab maintenance treatment in patients with metastatic urothelial carcinomaSemantic proximity Read ↗

Development and Validation of a Clinically Useful Nomogram for Predicting Sarcopenia in Bone Tumor PatientsSemantic proximity Read ↗

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.Semantic proximity Read ↗

The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy.Semantic proximity Read ↗

Optimized nutritional management mitigates short-term muscle mass loss in elderly frail patients with COVID-19: a randomized controlled trialSemantic proximity Read ↗

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.Semantic proximity Read ↗

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss.Semantic proximity Read ↗

Characterization of Body Composition Dynamics Throughout Treatment in Patients with Early-Stage Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.